Plain-English translation of NCT06218927 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This research study is watching how autologous hematopoietic stem cell transplantation affects bladder and urinary symptoms in people with multiple sclerosis. Researchers want to understand whether this stem cell treatment improves bladder function and quality of life better than standard disease-modifying medications. The study will compare people who receive the stem cell transplant to people receiving conventional MS treatments.
Multiple sclerosis can cause bothersome bladder and urinary problems that affect daily life, but we don't yet know if stem cell transplants help these symptoms more than current standard treatments do. This study aims to fill that gap by carefully tracking bladder health in both groups.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of two groups: either the stem cell transplant group or the standard medication group. Throughout the study, you will have regular visits to undergo bladder function tests, answer questions about your urinary symptoms and quality of life, and provide urine samples. The study will track your progress over time to see how your bladder health changes with your assigned treatment.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Czechia
Sponsor
University Hospital Ostrava
Enrollment target
~40 participants
Started
November 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.